NASDAQ:FATE - Fate Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.29
  • Forecasted Upside: -16.70 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$48.36
▲ +0.65 (1.36%)
1 month | 3 months | 12 months
Get New Fate Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FATE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FATE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$40.29
▼ -16.70% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $40.29, with a high forecast of $60.00 and a low forecast of $25.00. The average price target represents a -16.70% upside from the last price of $48.36.
Buy
The current consensus among 13 investment analysts is to buy stock in Fate Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/5/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/3/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/1/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2020BarclaysBoost Price TargetOverweight$40.00 ➝ $60.00High
i
8/13/2020Cantor FitzgeraldBoost Price TargetOverweight$32.00 ➝ $40.00Low
i
8/6/2020HC WainwrightReiterated RatingBuy$42.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/6/2020OppenheimerReiterated RatingBuy$40.00High
i
Rating by Matthew Biegler at Oppenheimer Holdings Inc.
6/9/2020OppenheimerInitiated CoverageBuy$34.00 ➝ $40.00Low
i
Rating by Matthew Biegler at Oppenheimer Holdings Inc.
6/9/2020Piper SandlerLower Price Target$63.00 ➝ $59.00Low
i
Rating by Edward Tenthoff at Piper Sandler
5/13/2020HC WainwrightInitiated CoverageBuy$42.00High
i
Rating by D. Chattopadhyay at HC Wainwright
5/12/2020BMO Capital MarketsBoost Price TargetMarket Perform$28.00 ➝ $29.00High
i
4/6/2020OppenheimerLower Price TargetOutperform$36.00 ➝ $34.00Low
i
Rating by Matthew Biegler at Oppenheimer Holdings Inc.
4/3/2020Piper SandlerBoost Price TargetHigh
i
Rating by Edward Tenthoff at Piper Sandler
4/3/2020WedbushBoost Price TargetOutperform$38.00 ➝ $41.00High
i
4/3/2020MizuhoReiterated RatingBuy$40.00High
i
Rating by Mara Goldstein at Mizuho
3/4/2020CitigroupBoost Price TargetBuy$26.00 ➝ $41.00High
i
3/4/2020BarclaysInitiated CoverageOverweight$40.00High
i
3/3/2020BMO Capital MarketsBoost Price Target$22.00 ➝ $28.00High
i
3/3/2020Roth CapitalBoost Price Target$20.00 ➝ $30.00High
i
3/3/2020BTIG ResearchBoost Price TargetBuy$27.00 ➝ $42.00High
i
3/3/2020Piper SandlerBoost Price TargetOverweight$28.00 ➝ $57.00High
i
3/3/2020GuggenheimBoost Price TargetBuy$25.00 ➝ $41.00High
i
3/3/2020OppenheimerBoost Price TargetOutperform$27.00 ➝ $36.00High
i
Rating by Matthew Biegler at Oppenheimer Holdings Inc.
2/26/2020MizuhoBoost Price TargetBuy$33.00 ➝ $40.00High
i
Rating by Mara Goldstein at Mizuho
2/14/2020WedbushBoost Price TargetOutperform$29.00 ➝ $33.00Medium
i
2/12/2020Wells Fargo & CompanyReiterated RatingOverweight$24.00 ➝ $34.00High
i
Rating by Jim Birchenough at Wells Fargo & Company
1/9/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$22.00High
i
Rating by Do Kim at BMO Capital Markets
12/30/2019MizuhoBoost Price TargetBuy ➝ Buy$27.00 ➝ $33.00High
i
Rating by Mara Goldstein at Mizuho
12/9/2019OppenheimerReiterated RatingBuy$27.00High
i
12/9/2019BMO Capital MarketsLower Price TargetOutperform$26.00 ➝ $22.00High
i
Rating by Do Kim at BMO Capital Markets
12/9/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$24.00High
i
11/12/2019SunTrust BanksInitiated CoverageBuy$25.00Low
i
11/6/2019MizuhoDowngradeBuyHigh
i
Rating by Mara Goldstein at Mizuho
11/6/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$24.00 ➝ $16.00High
i
9/30/2019Stifel NicolausInitiated CoverageBuy$27.00High
i
9/16/2019Piper Jaffray CompaniesLower Price TargetOverweight$30.00 ➝ $28.00Low
i
9/4/2019MizuhoReiterated RatingBuy$27.00High
i
Rating by Mara Goldstein at Mizuho
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$27.00High
i
8/7/2019BMO Capital MarketsSet Price TargetBuy$27.00High
i
Rating by Do Kim at BMO Capital Markets
8/7/2019WedbushBoost Price TargetOutperform$21.00 ➝ $26.00High
i
7/22/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$32.00 ➝ $32.00High
i
Rating by A. Young at Cantor Fitzgerald
7/12/2019CIBCInitiated CoverageOutperform ➝ Outperform$27.00High
i
7/12/2019OppenheimerInitiated CoverageOutperform$27.00 ➝ $27.00High
i
6/27/2019Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Top Pick$23.00 ➝ $30.00High
i
6/12/2019MizuhoInitiated CoverageBuy ➝ Buy$27.00High
i
6/7/2019Roth CapitalInitiated CoverageNeutral ➝ Neutral$20.00 ➝ $20.00Medium
i
Rating by T. Butler at Roth Capital
5/30/2019GuggenheimInitiated CoverageBuy$25.00High
i
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$20.00 ➝ $26.00Low
i
3/28/2019SVB LeerinkInitiated CoverageOutperform$20.00Medium
i
Rating by D. Graybosch at SVB Leerink LLC
3/6/2019Wells Fargo & CompanyBoost Price TargetOutperform$18.00 ➝ $24.00High
i
2/11/2019WedbushBoost Price TargetOutperform ➝ Outperform$19.00 ➝ $21.00Low
i
1/3/2019StephensDowngradeOverweight ➝ EqualMedium
i
11/5/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$17.00Low
i
9/25/2018Piper Jaffray CompaniesReiterated RatingOverweight$23.00High
i
9/18/2018Piper Jaffray CompaniesReiterated RatingOverweight$25.00High
i
8/7/2018WedbushReiterated RatingOutperform$19.00High
i
8/7/2018HC WainwrightReiterated RatingHold$12.00High
i
Rating by E. White at HC Wainwright
8/1/2018CitigroupInitiated CoverageBuy$20.00High
i
3/29/2018WedbushReiterated RatingOutperform$19.00Low
i
3/20/2018HC WainwrightReiterated RatingHold$12.00Medium
i
Rating by E. White at HC Wainwright
3/6/2018UBS GroupDowngradeOutperform ➝ Market PerformHigh
i
3/6/2018WedbushReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.00High
i
3/6/2018HC WainwrightDowngradeBuy ➝ Neutral$12.00High
i
Rating by E. White at HC Wainwright
3/6/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $20.00High
i
3/6/2018Wells Fargo & CompanyReiterated RatingOutperform$10.00 ➝ $19.00High
i
3/6/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Top Pick$20.00High
i
1/18/2018WedbushReiterated RatingOutperform$10.00 ➝ $7.00Medium
i
12/18/2017WedbushReiterated RatingOutperform$7.00Low
i
12/18/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$10.00Medium
i
12/13/2017HC WainwrightReiterated RatingBuy$7.00High
i
Rating by E. White at HC Wainwright
12/12/2017Raymond JamesReiterated RatingBuyMedium
i
Rating by Reni Benjamin at Raymond James
11/10/2017HC WainwrightReiterated RatingBuy$7.00N/A
i
Rating by E. White at HC Wainwright
11/2/2017HC WainwrightReiterated RatingBuyN/A
i
Rating by E. White at HC Wainwright
11/2/2017BMO Capital MarketsReiterated RatingBuy$7.00N/A
i
10/12/2017HC WainwrightReiterated RatingBuy ➝ Buy$7.00N/A
i
Rating by E. White at HC Wainwright
9/8/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$7.00Medium
i
Rating by M. Schmidt at SVB Leerink LLC
5/16/2017WedbushReiterated RatingOutperform$7.00High
i
3/20/2017HC WainwrightLower Price TargetBuy$8.00 ➝ $6.00Low
i
3/18/2017Roth CapitalSet Price TargetBuy$8.00Low
i
Rating by Mark Breidenbach at Roth Capital
3/17/2017WedbushReiterated RatingOutperform$7.00Medium
i
3/17/2017BMO Capital MarketsBoost Price TargetBuy$7.00Medium
i
2/28/2017WedbushReiterated RatingOutperform$7.00N/A
i
12/6/2016BMO Capital MarketsReiterated RatingOutperform$4.00N/A
i
Rating by do kim at BMO Capital Markets
11/8/2016WedbushLower Price TargetOutperform$8.00 ➝ $7.00N/A
i
9/22/2016Roth CapitalInitiated CoverageBuy$8.00N/A
i
Rating by M. Breidenbach at Roth Capital
8/9/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Shaunak Deepak at HC Wainwright
8/8/2016BMO Capital MarketsSet Price TargetBuy$4.00N/A
i
Rating by do kim at BMO Capital Markets
7/28/2016HC WainwrightInitiated CoverageBuy$9.00N/A
i
Rating by Mark Breidenbach at HC Wainwright
6/21/2016BMO Capital MarketsReiterated RatingOutperform$4.00N/A
i
Rating by Do Kim at BMO Capital Markets
6/21/2016SVB LeerinkReiterated RatingOutperform$4.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
5/10/2016BMO Capital MarketsReiterated RatingBuyN/A
i
Rating by Do Kim at BMO Capital Markets
5/10/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$4.00N/A
i
3/7/2016HC WainwrightReiterated RatingBuy$9.00N/A
i
Rating by Mark Breidenbach at HC Wainwright
3/5/2016SVB LeerinkInitiated CoverageBuyN/A
i
Rating by Paul Matteis at SVB Leerink LLC
3/4/2016SVB LeerinkReiterated RatingOutperform$8.00 ➝ $4.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
2/24/2016HC WainwrightReiterated RatingBuy$9.00N/A
i
12/7/2015SVB LeerinkReiterated RatingBuy$10.00 ➝ $8.00N/A
i
Rating by Sharon Stein at SVB Leerink LLC
12/7/2015WedbushReiterated RatingOutperform$10.00N/A
i
12/3/2015Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
11/5/2015CowenReiterated RatingOutperformN/A
i
(Data available from 10/26/2015 forward)
Fate Therapeutics logo
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $48.36
$47.06
$48.59

50 Day Range

MA: $39.91
$30.41
$49.04

52 Week Range

Now: $48.36
$12.59
$51.10

Volume

319,600 shs

Average Volume

1,018,262 shs

Market Capitalization

$4.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57